Stopping statins at age 75 did not increase mortality in people without prior cardiovascular disease, according to a recent clinical trial from France. The randomized, non‑inferiority study compared continuing versus discontinuing cholesterol‑lowering medication in older adults deemed at low risk for heart disease and found no evidence of higher death rates over the follow‑up period.
The trial, published in Lancet Healthy Longevity, did not conclude that halting statins is universally preferable to ongoing treatment. Investigators framed the results as evidence that, for this selected group, discontinuation may be a reasonable option to consider. The authors emphasised that the study’s design tested whether stopping was not meaningfully worse than continuing therapy, rather than showing a clear benefit from stopping.
Clinical implications are limited by the trial’s population and context. Participants were older adults without established cardiovascular disease and were managed within the French healthcare system; the researchers caution that these findings may not apply to people with prior heart attacks, strokes, or higher baseline cardiovascular risk. The study’s outcome focused on death rates, and the report advises clinicians to evaluate individual risk factors, potential side effects, and patient preferences when discussing medication changes.
Commenting on the broader context, the investigators and independent experts recommend shared decision‑making between patients and their clinicians rather than abrupt changes to prescribing practices. Recent guideline shifts that broaden statin considerations to younger adults add complexity to lifelong treatment decisions, underscoring the need for further trials and real‑world data across diverse populations. Until additional evidence is available, the study’s authors advise personalised discussions about the risks and benefits of continuing versus stopping statin therapy for those aged 75 and older without cardiovascular disease.
